Work

FIGURE 2 from Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

Year: 2023

Type: other

Abstract: Maximum CA 19-9 responses in the expansion cohort. Figure shows the CA 19-9 percent change from baseline according to response of progressive disease (PD), SD, PR, CR, or not evaluable (NE).

DOI: 10.1158/2767-9764.24043025.v1

Authors: H. Catherine Wilbur, Jennifer N. Durham, Su Jin Lim, Katrina Purtell, Katherine M. Bever, Daniel A. Laheru, Ana De Jesus-Acosta, Nilofer S. Azad, Bradley Wilt, Luis A. Diaz, Dung T. Le, Hao Wang

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4386216101

Cites:

Cited by:

Related to: 10